What smart money is saying about Integer Holdings
4 funds in our archive have pitched Integer Holdings, most recently Cooke & Bieler SMID Cap Value Equity in September 2026.
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2024 and Q3 2026, 8 fund letters reported a position in Integer Holdings, with 2 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 7 | 0 | 2 | 2 |
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q4 2024 | 0 | 0 | 0 | 2 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 8 positions · 2 moves
- HoldsHeartland Value FundSeptember 2026
“One of our holdings receiving strategic interest is Integer Holdings (ITGR) , a leading global medical device contract development and manufacturing organization (CDMO).”
Integer Holdings - September 2026
“Selection within Health Care, a space that has been battered over the last several years outside of speculative areas like biotechnology, contributed most, with Charles River Laboratories, Integer Holdings, and CONMED signicantly outperforming benchmark constituents.”
Integer Holdings - September 2026
“Four positions were eliminated from the portfolio during the third quarter. Integer Holdings is a medical device contract manufacturer. We initiated a position in late 2024, attracted by steady growth in the neurological and cardiovascular end markets, an accelerating trend of OEM production outsourcing and a skilled management team with a clear operational improvement agenda. We exited the position following the announcement that private equity firm KKR would acquire the company at a 20% premium to the prior day’s closing price.”
Integer Holdings - September 2026
“Relative to the Russell 2000, industrials and healthcare were the top two sector contributors to the strategy’s relative outperformance of the Russell 2000, with information technology, real estate, materials, consumer staples, utilities and communication services also contributing positively. Our -7% industrial sector return was much better than the benchmark’s -15%. Within industrials, the combination of an overweight position and better stock performance in the professional services industry was the primary driver of outperformance in the sector. In healthcare, our +13% return compared favorably to the -1% return for the benchmark. Our holdings in the providers and services industry were +12% compared to -7% in the benchmark, and our holdings in the equipment and supplies industry were +26% versus +10% in the benchmark. Integer Holdings was a notable contributor in the quarter as the company received a buyout offer from Kohlberg Kravis Roberts & Company at the beginning of August.”
Integer Holdings - September 2026
“Largest Contributors Charles River Laboratories International (CRL), the world’s largest provider of outsourced nonclinical drug development services, was the largest contributor. The company reported better than expected quarterly bookings and earnings, providing solid support for our thesis that demand is recovering after a period of cyclical contraction. Integer Holdings (ITGR), a leading medical device outsourced design and manufacturing company, was the second-largest contributor.”
Integer Holdings - September 2026
“One of our holdings receiving strategic interest is Integer Holdings (ITGR), a leading global medical device contract development and manufacturing organization (CDMO).”
Integer Holdings - September 2026
“We have exited the position.”
Integer Holdings - June 2026
“CONMED is expected to report a year-over-year revenue decline resulting from a recent divestiture, and Integer Holdings lowered its fiscal year 2026 revenue guidance, citing slower-than-expected growth in pulse field ablation products, causing shares of both companies to contract.”
Integer Holdings
Also mentioned · 1
These funds discuss Integer Holdings as a competitor, benchmark or comparable, without disclosing a position in it.
- MentionedBoussard & Gavaudan Gestion Sas Market InsightsJuly 2026
“Meanwhile the announced acquisition of Integer Holdings by KKR at the end of the month further illustrates the strength of the current corporate activity environment.”
Integer Holdings
Fund coverage · 4 theses
- Cooke & Bieler SMID Cap Value EquitySeptember 2026
Integer Holdings is a leading outsourced medical device design and manufacturing company with an unusually attractive valuation that drew private equity interest and a takeout by KKR.
Read the full thesis - Heartland Value FundSeptember 2026
Integer Holdings is a global medical device CDMO that the manager liked for its research-backed conviction, insider buying, and strategic optionality that ultimately led to a sale at a premium.
Read the full thesis - Riverwater Small CapDecember 2024
Integer Holdings Corporation (ITGR) is a leading medical device outsourcing manufacturer with a strong track record of revenue and earnings growth, making it well-positioned for stock appreciation.
Read the full thesis - Artisan US Small Cap Growth StrategyDecember 2024
Integer is a leading manufacturer of medical devices with strong growth potential due to its focus on high-margin implantable devices and transcatheter therapies, benefiting from market trends and operational efficiency.
Read the full thesis
Read every full thesis on Integer Holdings
Read all 4 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→